Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13152990 | 0.80 | — | — | |
| SCHEMBL20160537 | 0.79 | SLC6A4 (0.37) | C5AR1GPR119 | |
| SCHEMBL2743255 | 0.73 | GPR119 (0.34) | GPR119 | |
| SCHEMBL2228600 | 0.72 | ALDH1A1 (0.40) | — | |
| SCHEMBL20160815 | 0.72 | C5AR1 (0.35) | C5AR1GPR119 | |
| SCHEMBL9810124 | 0.72 | C5AR1 (0.33) | C5AR1 | |
| SCHEMBL3591536 | 0.71 | GPR119 (0.37) | C5AR1GPR119 | |
| SCHEMBL13900936 | 0.69 | TDP1 (0.32) | — | |
| SCHEMBL19115283 | 0.67 | — | — | |
| SCHEMBL372402 | 0.67 | LMNA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202840-B2 | Compounds for the treatment or alleviation of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2025-01-21 | — | — | US | disclosed |
| EP-3802528-B1 | NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES | AC IMMUNE SA (CH) | 2022-07-06 | — | — | EP | disclosed |
| EP-3802528-B1 | NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES | AC IMMUNE SA (CH) | 2022-07-06 | — | — | EP | disclosed |
| US-20210214371-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2021-07-15 | — | — | US | disclosed |
| US-20210214371-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2021-07-15 | — | — | US | disclosed |
| EP-3802528-A1 | NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES | AC Immune SA (CH) | 2021-04-14 | — | — | EP | disclosed |
| WO-2019233745-A1 | NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES | AC IMMUNE SA (CH) | 2019-12-12 | — | — | WO | disclosed |
| WO-2019233745-A1 | NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES | AC IMMUNE SA (CH) | 2019-12-12 | — | — | WO | disclosed |
| EP-0888351-B1 | PYRIMIDO 5,4-D]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | THOMAE GMBH DR K (DE) | 2003-10-15 | — | — | EP | disclosed |
| EP-0888351-A1 | PYRIMIDO 5,4-D]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | Dr. Karl Thomae GmbH (DE) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997032880-A1 | PYRIMIDO[5,4-D]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | DR. KARL THOMAE GMBH (DE) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202840-B2 | Compounds for the treatment or alleviation of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | C5AR1 4829/4885GPR119 3071/4885 |
| US-20210214371-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | C5AR1 4771/4885GPR119 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.